Tracks molecular markers in people with head and neck squamous cell cancer
Collects tissue and blood samples to profile molecular markers during standard treatment.
Plain-language title generated from the registry record
Registry title: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
Key facts
- Where
- San Juan, Puerto RicoSee the site
Where in Puerto Rico
- Pan American Cancer for OncologySan Juan, Puerto RicoNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Tempus AI
- Trial code
- NCT06163534
- Record updated
- 3 September 2026
- Original description
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.Read full original descriptionShow less
TEMPUS PHOENIX HNSCC STUDY: A Longitudinal Multi-Omic Biomarker Profiling Study of Patients With Head & Neck Squamous Cell Carcinoma (HNSCC)
The study is a prospective, longitudinal, non-interventional, multicenter study of participants with HNSCC who will have tissue and blood based molecular biomarker profiling during their standard of care treatment.
Inclusion: ≥18 years of age; Willing and able to provide informed consent; Histologically- or cytologically-confirmed metastatic or unresectable, recurrent HNSCC unsuitable for local therapies; Intended for first line anti-PD1 or PDL1 monotherapy or combination therapy; Must submit tumor tissue sample representative of current disease per laboratory manual.
Exclusion: Relapse or recurrence within 6 months of first line chemotherapy and / or chemoradiotherapy; Clinical evidence of an active second invasive malignancy within <2 years of enrollment with the exception of stable prostate cancer on watchful waiting, in situ cervical cancer, in situ breast carcinoma or localized non-melanoma skin cancers; Non-squamous histologies (eg, nasopharynx or salivary gland); Tumors that are PD-L1 negative (CPS <1); Unable to comply with study procedures (i.e., not willing or able to have additional blood samples collected).